Genmab — September 2019
-
Jeg syntes også kurven ligner en vommitting camel med strithale i dag...
-
1700 : BofA/Merrill analyst Sachin Jain upgraded Genmab to Buy from Neutral with an increased price target of DKK1700. Multiple pipeline updates over the next 12 months should allow the investment thesis to begin to move beyond Darzalex and be a catalyst for the shares, Jain tells investors in a research note.
-
That's nice EL. So an increase on 250 kr.
-
Ofa på ECTRIMS er kl 14:15 https://www.professionalabstracts.com/ectrims2019/programme-ectrims2019.pdf
-
Live fra ECTRIMS https://multiple-sclerosis-research.org/2019/09/google-hangout-live/
-
Den oprindelige pressemeddelelse fra Novartis taler om "wonderful news for patients" og "powerful study results" og "highly attractive treatment option" og "potent, safe and convenient therapy", så vi må vel antage, at det ikke er sådan helt skidt...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind